CADL vs. TRVI, AMLX, CALT, MAZE, ELVN, PRAX, IMTX, WVE, DNTH, and ORIC
Should you be buying Candel Therapeutics stock or one of its competitors? The main competitors of Candel Therapeutics include Trevi Therapeutics (TRVI), Amylyx Pharmaceuticals (AMLX), Calliditas Therapeutics AB (publ) (CALT), Maze Therapeutics (MAZE), Enliven Therapeutics (ELVN), Praxis Precision Medicines (PRAX), Immatics (IMTX), WAVE Life Sciences (WVE), Dianthus Therapeutics (DNTH), and Oric Pharmaceuticals (ORIC). These companies are all part of the "pharmaceutical products" industry.
Candel Therapeutics vs. Its Competitors
Trevi Therapeutics (NASDAQ:TRVI) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.
95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 18.3% of Trevi Therapeutics shares are held by company insiders. Comparatively, 16.6% of Candel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Trevi Therapeutics currently has a consensus target price of $21.75, suggesting a potential upside of 124.00%. Candel Therapeutics has a consensus target price of $20.00, suggesting a potential upside of 209.12%. Given Candel Therapeutics' higher possible upside, analysts clearly believe Candel Therapeutics is more favorable than Trevi Therapeutics.
Candel Therapeutics' return on equity of -41.00% beat Trevi Therapeutics' return on equity.
In the previous week, Trevi Therapeutics had 4 more articles in the media than Candel Therapeutics. MarketBeat recorded 8 mentions for Trevi Therapeutics and 4 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of 0.86 beat Trevi Therapeutics' score of 0.45 indicating that Candel Therapeutics is being referred to more favorably in the news media.
Trevi Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Comparatively, Candel Therapeutics has a beta of -0.94, suggesting that its stock price is 194% less volatile than the S&P 500.
Trevi Therapeutics has higher earnings, but lower revenue than Candel Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Trevi Therapeutics beats Candel Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Candel Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CADL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Candel Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CADL) was last updated on 10/13/2025 by MarketBeat.com Staff
